Philip E. Morris

724 total citations
31 papers, 565 citations indexed

About

Philip E. Morris is a scholar working on Molecular Biology, Organic Chemistry and Infectious Diseases. According to data from OpenAlex, Philip E. Morris has authored 31 papers receiving a total of 565 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 11 papers in Organic Chemistry and 8 papers in Infectious Diseases. Recurrent topics in Philip E. Morris's work include Biochemical and Molecular Research (15 papers), HIV/AIDS drug development and treatment (8 papers) and Adenosine and Purinergic Signaling (7 papers). Philip E. Morris is often cited by papers focused on Biochemical and Molecular Research (15 papers), HIV/AIDS drug development and treatment (8 papers) and Adenosine and Purinergic Signaling (7 papers). Philip E. Morris collaborates with scholars based in United States and Canada. Philip E. Morris's co-authors include Donald E. Kiely, John A. Montgomery, Tracy L. Hutchison, J. M. Beaton, Shanta Bantia, Hollis S. Kezar, Peter C. Tyler, Sandya L. Ananth, Arthur J. Elliott and Vern L. Schramm and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of Organic Chemistry and Biochemical Pharmacology.

In The Last Decade

Philip E. Morris

31 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip E. Morris United States 16 331 237 103 81 78 31 565
Ioannis Papanastasiou Greece 15 226 0.7× 362 1.5× 143 1.4× 38 0.5× 11 0.1× 47 708
P. Anantha Reddy United States 10 165 0.5× 93 0.4× 35 0.3× 41 0.5× 14 0.2× 21 421
Ram Chandra Mishra India 14 313 0.9× 311 1.3× 34 0.3× 48 0.6× 79 1.0× 28 543
Mark D. Andrews United Kingdom 14 228 0.7× 290 1.2× 99 1.0× 18 0.2× 4 0.1× 25 664
Ulrika Nilsson Sweden 14 264 0.8× 42 0.2× 38 0.4× 16 0.2× 16 0.2× 17 639
Halina T. Serafinowska United Kingdom 14 372 1.1× 356 1.5× 40 0.4× 60 0.7× 6 0.1× 24 672
Kamel Metwally Egypt 15 227 0.7× 304 1.3× 34 0.3× 28 0.3× 4 0.1× 39 728
Amit N. Pandya India 14 85 0.3× 242 1.0× 62 0.6× 44 0.5× 16 0.2× 21 467
Huiqiang Zhou United States 14 309 0.9× 200 0.8× 25 0.2× 40 0.5× 7 0.1× 21 540
Michael McNaughton Belgium 11 204 0.6× 160 0.7× 30 0.3× 42 0.5× 38 0.5× 11 428

Countries citing papers authored by Philip E. Morris

Since Specialization
Citations

This map shows the geographic impact of Philip E. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip E. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip E. Morris more than expected).

Fields of papers citing papers by Philip E. Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip E. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip E. Morris. The network helps show where Philip E. Morris may publish in the future.

Co-authorship network of co-authors of Philip E. Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Philip E. Morris. A scholar is included among the top collaborators of Philip E. Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip E. Morris. Philip E. Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morris, Philip E., et al.. (2009). Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor—Part I. Bioorganic & Medicinal Chemistry Letters. 19(10). 2624–2626. 6 indexed citations
2.
Morris, Philip E., et al.. (2009). Synthesis of labeled BCX‐4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Testing and Analysis. 1(3). 125–127. 3 indexed citations
3.
Morris, Philip E., et al.. (2009). Development of a Practical Synthesis of a Purine Nucleoside Phosphorylase Inhibitor: BCX-4208. Organic Process Research & Development. 13(5). 928–932. 21 indexed citations
4.
Morris, Philip E., et al.. (2009). Alternative route towards the convergent synthesis of a human purine nucleoside phosphorylase inhibitor—forodesine HCl. Tetrahedron Letters. 50(37). 5198–5200. 5 indexed citations
5.
Morris, Philip E., et al.. (2006). Synthesis of a potent 5′-methylthioadenosine/S-adenosylhomocysteine (MTAN) inhibitor. Bioorganic & Medicinal Chemistry Letters. 16(10). 2662–2665. 7 indexed citations
6.
Chand, Pooran, Pravin L. Kotian, Philip E. Morris, et al.. (2005). Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase. Bioorganic & Medicinal Chemistry. 13(7). 2665–2678. 37 indexed citations
7.
Kezar, Hollis S., et al.. (2005). Synthesis and Pharmacokinetic and Pharmacodynamic Evaluation of the Forodesine HCl Analog BCX-3040. Nucleosides Nucleotides & Nucleic Acids. 24(10-12). 1817–1830. 3 indexed citations
8.
Subasinghe, Nalin L., Carl R. Illig, Matthias Rudolph, et al.. (2004). A novel series of potent and selective small molecule inhibitors of the complement component C1s. Bioorganic & Medicinal Chemistry Letters. 14(12). 3043–3047. 18 indexed citations
9.
Ananth, Sandya L., et al.. (2004). Synthesis of a Potent Transition-State Inhibitor of 5‘-Deoxy-5‘-methylthioadenosine Phosphorylase. Journal of Medicinal Chemistry. 47(6). 1322–1324. 18 indexed citations
10.
11.
Kezar, Hollis S., Tracy L. Hutchison, Peter C. Tyler, & Philip E. Morris. (2001). Synthesis of deuterated‐BCX‐1777, a potent inhibitor of purine nucleoside phosphorylase. Journal of Labelled Compounds and Radiopharmaceuticals. 45(1). 71–78. 1 indexed citations
12.
Bantia, Shanta, Patrick J. Miller, Cynthia Parker, et al.. (2001). Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent. International Immunopharmacology. 1(6). 1199–1210. 72 indexed citations
13.
Morris, Philip E., et al.. (2000). Synthesis and Biological Activity of a Novel Class of Purine Nucleoside Phosphorylase Inhibitors. Nucleosides Nucleotides & Nucleic Acids. 19(1-2). 379–404. 19 indexed citations
14.
Hutchison, Tracy L. & Philip E. Morris. (1999). Synthesis of deuterated-BCX-34 (peldesine). Journal of Labelled Compounds and Radiopharmaceuticals. 42(13). 1235–1244. 1 indexed citations
15.
Morris, Philip E. & John A. Montgomery. (1998). Inhibitors of the enzyme purine nucleoside phosphorylase. Expert Opinion on Therapeutic Patents. 8(3). 283–299. 19 indexed citations
16.
Morris, Philip E., et al.. (1993). Indolealkylamine metabolism: Synthesis of deuterated indolealkylamines as metabolic probes. Journal of Labelled Compounds and Radiopharmaceuticals. 33(6). 455–465. 6 indexed citations
17.
Tolbert, Lelland C., et al.. (1992). Stereospecific effects of ascorbic acid and analogues on D1 and D2 agonist binding. Life Sciences. 51(12). 921–930. 31 indexed citations
18.
Morris, Philip E., et al.. (1989). The Isomeric Composition ofD-ribo-hexos-3-ulose(3-keto-D-glucose) in Aqueous Solution1. Journal of Carbohydrate Chemistry. 8(3). 515–530. 15 indexed citations
19.
Morris, Philip E. & J. M. Beaton. (1983). Facilitation of an operant task in the rat following injection of whole brain extract. Pharmacology Biochemistry and Behavior. 19(2). 241–244. 1 indexed citations
20.
Barker, Steven A., J. M. Beaton, Samuel T. Christian, John A. Monti, & Philip E. Morris. (1982). Comparison of the brain levels of N,N-dimethyltryptamine and α,α,β,β-tetradeutero-N,N-dimethyltryptamine following intraperitoneal injection. Biochemical Pharmacology. 31(15). 2513–2516. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ioannis Papanastasiou Breakdown of academic impact, for papers by P. Anantha Reddy Breakdown of academic impact, for papers by Ram Chandra Mishra Breakdown of academic impact, for papers by Mark D. Andrews Breakdown of academic impact, for papers by Ulrika Nilsson Breakdown of academic impact, for papers by Halina T. Serafinowska Breakdown of academic impact, for papers by Kamel Metwally Breakdown of academic impact, for papers by Amit N. Pandya Breakdown of academic impact, for papers by Huiqiang Zhou Breakdown of academic impact, for papers by Michael McNaughton
Rankless by CCL
2026